Home Tags HER2

Tag: HER2

First Patient with Advanced Solid Tumors with HER2 Expression Dosed in...

A first patient with advanced solid tumors with HER2 Expression was dosed in a phase I clinical trial with ADCT-502. The investigational drug being...

Bridging HER2 and Prolactin Receptor Improves Efficacy of an HER2 ADCs.

Authors: Andreev J, Thambi N, Perez Bay AE, Delfino FJ, Martin JH, Kelly MP, Kirshner JR, Rafique A, Kunz A, Nittoli T, MacDonald D,...
Featured Image: Doctor explaining diagnosis to her patient Courtesy: © 2017 Fotolia. Used with permission.

MM-302 Misses Endpoint in Phase II Hermione Trial

Following a recent independent Data and Safety Monitoring Board (DSMB) recommendation and subsequent futility analysis, Cambridge, Massachusetts-based Merrimack Pharmaceuticals, has decided to stop the...

F-star Implements Genedata Biologics as an Integrated Workflow Platform for Bispecific...

F-star, a clinical stage biopharmaceutical company developing bispecific antibody immuno-oncology products selected for their potential to transform the treatment of cancer, has licensed Genedata Biologics™...

Efficient Payload Delivery by a Bispecific Antibody-Drug Conjugate Targeting HER2 and...

Authors: De Goeij BE, Vink T, Ten Napel H, Breij EC, Satijn D, Wubbolts R, Miao D, Parren PW. Title: Efficient Payload Delivery by a Bispecific Antibody-Drug...

U.S. FDA Accepts Investigational New Drug Application for Mersana’s Lead Antibody-Drug...

The U.S. Food and Drug Administration (FDA) cleared Mersana Therapeutics’ Investigational New Drug (IND) application to begin Phase I clinical trials for its lead...

Phase I Study Shows Daichi Sankyo’s Anti-HER2 Antibody-drug Conjugate DS-8201a to...

Safety and preliminary efficacy data from a phase I study of DS-8201a (Daiichi Sankyo Company), a novel investigational HER2-targeting antibody drug conjugate or ADC,...

Anti-HER2 ADC SYD985 to be Evaluated in Expanded Cohort of HER2+...

Dutch pharmaceutical company Synthon Biopharmaceuticals has initiated the second part of an ongoing phase I clinical trial with its investigational anti-HER2 antibody-drug conjugate or ADC,...

American Association for Cancer Research (AACR) – What to Expect at...

This year, the American Association for Cancer Research (AACR) will host their annual meeting from April 16 to 20, 2016 in the Ernest N....

ARX788 First-In-Human Phase I Clinical trial in HER2 cancer patients

A First-In-Human phase I clinical trial with ARX788, an site-specific antibody-drug conjugate being developed by Ambrx® and Zhejiang Medicine has been initiated as a multicenter...

FEATURED RESOURCES